Outlook Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-07-31. 2 holders' latest filing reports 5% or more of common stock, $0.01 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| GMS Ventures & Investments | 16.4% | 42,631,142 | SCHEDULE 13D/A, 2026-08-14 | 2026-08-12 |
| CVI Investments, Inc. | 9.9% | 24,713,908 | SCHEDULE 13G, 2026-08-19 | 2026-08-12 |
| Empery Asset Management, LP | 4.99% | 2,332,948 | SCHEDULE 13G/A, 2025-10-21 | 2025-09-30 |
| Great Point Partners, LLC | 4.99% | 2,220,000 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Mitchell P. Kopin | 4.99% | 5,990,447 | SCHEDULE 13G, 2026-04-24 | 2026-04-22 |
| Sphera Funds Management Ltd. | 4.69% | 3,153,856 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| Tang Capital Management, LLC | 3.4% | 1,500,000 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Purpose of Transaction (Item 4)
GMS Ventures & Investments
Item 4 of the Schedule 13D is hereby amended to add the following after the last paragraph: On August 12, 2026, the Issuer entered into the sale of an aggregate of 55,555,556 Shares and accompanying Warrants to acquire up to an aggregate of 55,555,556 Shares in a registered underwritten public offering (the "August 2026 Offering"). GMS Ventures purchased 2,525,252 Shares and accompanying Warrants to purchase 2,525,252 Shares in the Offering, at a combined purchase price per Share and accompanying Warrant of $0.99, for an aggregate purchase price of approximately $2.5 million. Each Warrant will have an initial exercise price per share of $1.10, subject to certain customary adjustments for recapitalizations, stock splits and similar actions. The Warrants will be exercisable immediately and will expire five years from the date of issuance. The August 2026 Offering closed on August 14, 2026.Item 4 of the SCHEDULE 13D/A filed 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-31 | Empery Asset Management, LP | 7.57% | SCHEDULE 13G |
| 2025-08-14 | Great Point Partners, LLC | 4.99% | SCHEDULE 13G/A |
| 2025-08-14 | Tang Capital Management, LLC | 3.4% | SCHEDULE 13G/A |
| 2025-10-21 | Empery Asset Management, LP | 4.99% | SCHEDULE 13G/A |
| 2026-02-05 | Sphera Funds Management Ltd. | 4.69% | SCHEDULE 13G/A |
| 2026-04-24 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G |
| 2026-06-01 | GMS Ventures & Investments | 22.9% | SCHEDULE 13D/A |
| 2026-08-14 | GMS Ventures & Investments | 16.4% | SCHEDULE 13D/A |
| 2026-08-19 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Outlook Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.